p-Diethylaminobenzylanilid | 33739-89-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-Diethylaminobenzylanilid
• 英文别名: 4-diethylamino-benzoic acid anilide；4-Diaethylamino-benzoesaeure-anilid；4-(diethylamino)-N-phenylbenzamide
• CAS: 33739-89-8
• 化学式: C₁₇H₂₀N₂O
• 分子量: 268.359
• InChiKey: NYGIDOGIQJQROB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(N,N-二乙氨基)-苯甲酸 在 五氯化磷 作用下， 生成 p-Diethylaminobenzylanilid
  参考文献：
  名称：

  Meisenheimer; v. Budkewicz; Kananow, Justus Liebigs Annalen der Chemie, 1921, vol. 423, p. 90,91

  摘要：

  DOI：

文献信息

• BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS
  申请人：Galley Guido

  公开号：US20090036420A1

  公开（公告）日：2009-02-05

  The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.

  本发明涉及使用式I中的化合物治疗中枢神经系统疾病的方法，其中X、R1、R2、R3、R4、R5、R6、R7和R8如说明书中所定义，并且包括药学上可接受的酸盐。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：EP2350311B1

  公开（公告）日：2013-12-25
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：MethylGene Inc.

  公开号：EP1735319B1

  公开（公告）日：2017-05-03
• THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2182935A1

  公开（公告）日：2010-05-12
• [EN] THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZAMIDE POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016088A1

  公开（公告）日：2009-02-05

  The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.